Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)

20231 citationsJournal Article

Authors

Li G · MedSol Clinical Research Center

Yuebing Li · Cleveland Clinic

Tuan Vu · University of South Florida

Denis Korobko · Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital

Marek Śmiłowski · Medical University of Silesia

Li Liu · Argenx (Belgium)

Sophie Steeland

Abstract

To confirm dose selection and rationale of using the reduction of total immunoglobulin G (IgG) levels as a pharmacodynamic (PD) marker of noninferiority for subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20).

Topics & Keywords

Myasthenia Gravis and Thymoma Antifungal resistance and susceptibility Autoimmune Bullous Skin Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 100, Issue 17_supplement_2

DOI: 10.1212/wnl.0000000000203765

Field-Weighted Citation Impact: 0.21